心脏成纤维细胞分泌CRLF1促进人类肥厚型心肌病
该研究对269例梗阻性肥厚型心肌病(HCM)患者肥厚的室间隔组织进行整合分析,发现心脏成纤维细胞分泌的CRLF1在不同遗传背景的HCM中均显著升高,并通过LIFR-JAK1/2-STAT3通路驱动心肌细胞肥大。遗传敲除成纤维细胞Crlf1或药物抑制下游通路可显著减轻小鼠和人类HCM模型的疾病表型,提示CRLF1是HCM的通用治疗靶点。
要点
- CRLF1在遗传异质性HCM患者肥厚心肌和循环中显著升高,主要由活化成纤维细胞分泌。
- CRLF1通过LIFR-JAK1/2-STAT3信号通路促进小鼠和人类心肌细胞肥大。
- 敲除成纤维细胞Crlf1或抑制下游通路可减轻HCM模型疾病表型。
核心结论
- CRLF1介导的旁分泌机制是不同遗传背景HCM的共同致病通路,CRLF1可作为通用治疗靶点。
研究设计与样本
- 对269例接受室间隔心肌切除术的梗阻性HCM患者肥厚室间隔组织进行靶向肌节基因筛查、bulk RNA测序和加权基因共表达网络分析。
- 使用Myh6 R404Q/+小鼠模型进行跨物种验证,并通过单细胞RNA测序、生化实验及功能获得/缺失研究评估候选因子。
主要发现
- CRLF1主要由活化的心脏成纤维细胞分泌,在遗传异质性HCM患者肥厚心肌和循环中显著升高。
- CRLF1激活LIFR-JAK1/2-STAT3级联,促进小鼠和人类HCM模型的心肌细胞肥大。
- 成纤维细胞中Crlf1基因敲除或药理学抑制其下游通路可显著减轻疾病表型。
临床怎么用
- CRLF1及其下游LIFR-JAK1/2-STAT3通路可作为HCM的潜在通用治疗靶点,尤其适用于缺乏明确遗传缺陷的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertrophic cardiomyopathy (HCM), the most common inherited cardiac disorder and a leading cause of sudden cardiac death in young adults, exhibits substantial genetic and clinical heterogeneity. Although sarcomere gene sequence variations account for a major proportion of HCM cases, nearly half of patients lack identifiable genetic defects, implying the involvement of undiscovered mechanisms that may converge on a common pathogenic pathway. However, a unified molecular basis underlying HCM pathogenesis remains undefined. METHODS: We conducted an integrated analysis of hypertrophied interventricular septum tissues from 269 patients with obstructive HCM undergoing surgical myectomy. Targeted sarcomere gene screening, bulk RNA sequencing, and weighted gene coexpression network analysis were used to identify candidate drivers of disease. Cross-species validation was performed using a Myh6 R404Q/+ mouse model. Single-cell RNA sequencing delineated the cellular source of key factors, and biochemical assays and gain- and loss-of-function studies were used to assess their functional relevance. CRLF1 (cytokine receptor-like factor 1) emerged as a candidate mediator and was further evaluated in vitro and in vivo. RESULTS: CRLF1, predominantly secreted by activated cardiac fibroblasts, emerged as a key paracrine factor driving cardiomyocyte hypertrophy across patients with genetically heterogeneous HCM. CRLF1 levels were significantly elevated in hypertrophied myocardium and circulation. CRLF1 activated the LIFR (leukemia inhibitory factor receptor)-JAK1/2 (Janus kinase)-STAT3 (signal transducer and activator of transcription 3) signaling cascade to promote hypertrophy in both murine and human HCM models. Genetic ablation of Crlf1 in fibroblasts or pharmacological inhibition of its downstream pathway markedly attenuated disease phenotypes. CONCLUSIONS: Our findings uncover a common, nongenetic paracrine mechanism underlying HCM pathogenesis and establish CRLF1 as a promising universal therapeutic target for this heterogeneous disease.
引用
- Lin B, Wang J, Li C, et al. CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. Circulation. 2026. PMID: 41838796. doi:10.1161/CIRCULATIONAHA.125.075290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。